Contract Services Pre-Clinical Outsourcing
JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial
-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...
August 18, 2026 | News
6 Radiopharmaceutical Programmes and Sites to Watch in APAC
Radioligand therapy is the one modality a region cannot buy its way into late. A vial of lutetium-177 loses half its therapeutic activity in roughly six an...
August 18, 2026 | Analysis
Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303
Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...
July 24, 2026 | News
Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...
July 21, 2026 | News
China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?
THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...
July 16, 2026 | Analysis
WuXi Biologics' Hebei Facility Clears US FDA Pre-License Inspection for Commercial Manufacturing
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...
July 13, 2026 | News
Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site
Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...
July 01, 2026 | News
Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires
For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...
June 25, 2026 | Analysis
WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...
June 25, 2026 | News
Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision
Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform ...
June 10, 2026 | News
VectorBuilder Secures European Patent For MiniVec Plasmid System Advancing Genetic Medicine Development
Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines VectorBuilder, a global leader in ...
May 06, 2026 | News
Samsung Bioepis Co., Ltd. And ATLATL Innovation Center Forge APAC Open Innovation Pact To Accelerate Early Stage Biotech Growth
Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and deve...
April 29, 2026 | News
WuXi Biologics Advances Chengdu Microbial Manufacturing Site Toward GMP Production
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the structural completion and k...
April 27, 2026 | News
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturin...
April 24, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
